Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI

Background: Biliary tract cancers (BTCs) are aggressive in nature, often presenting asymptomatically until they are diagnosed at an advanced stage. Surgical resection or liver transplantation are potential curative options. However, a large proportion of patients present with incurable locally advanced or metastatic disease and most of these patients are only eligible for palliative chemotherapy or best supportive care. More recently, targeted therapies have proven beneficial in a molecularly selected subgroup of patients with cholangiocarcinoma who have progressed on previous lines of systemic treatment. However, only a minority of patients with BTCs whose tumours harbour specific molecular alterations can access these therapies. Methods: In relation to ADCs, studies regarding use of antibody-drug conjugates in cancer, particularly in BTCs, were searched in Embase (1974 to 2024) and Ovid MEDLINE(R) (1946 to 2024) to obtain relevant articles. Examples of current clinical trials utilising ADC treatment in BTCs were extracted from the ClinicalTrials.gov trial registry. Conclusions: Overall, this review has highlighted that ADCs have shown encouraging outcomes in cancer therapy, and this should lead to further research including in BTCs, where treatment options are often limited. The promising results observed with ADCs in various cancers underscore their potential as a transformative approach in oncology, warranting continued exploration and development and the need for education on the management of their specific toxicities. By addressing current challenges and optimising ADC design and application, future studies could potentially improve treatment outcomes for patients with BTCs and beyond, potentially in both early and advanced stage settings.

Mol Cancer Ther. 2015 Apr;14(4):952-63. (PMID: 25646013)
Cancer Control. 2023 Jan-Dec;30:10732748231211764. (PMID: 37926828)
Breast. 2016 Oct;29:170-7. (PMID: 27526299)
Genome Med. 2015 Jul 29;7(1):80. (PMID: 26221189)
Biomolecules. 2020 Oct 23;10(11):. (PMID: 33113997)
Pharmacol Res. 2019 Oct;148:104398. (PMID: 31415916)
Am Soc Clin Oncol Educ Book. 2016;35:e194-203. (PMID: 27249723)
Lancet Oncol. 2020 Jun;21(6):796-807. (PMID: 32416072)
Antibodies (Basel). 2020 Jul 20;9(3):. (PMID: 32698317)
J Exp Clin Cancer Res. 2023 Oct 25;42(1):280. (PMID: 37880707)
Nature. 1975 Aug 7;256(5517):495-7. (PMID: 1172191)
Hepatology. 2014 Apr;59(4):1427-34. (PMID: 24122810)
Antibodies (Basel). 2018 Feb 07;7(1):. (PMID: 31544862)
Science. 1993 Jul 9;261(5118):212-5. (PMID: 8327892)
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):483-485. (PMID: 33307876)
Int J Cancer. 2013 Jul;133(1):1-13. (PMID: 23280579)
Biomark Insights. 2010 Feb 09;5:9-20. (PMID: 20212918)
Front Oncol. 2023 Dec 20;13:1259784. (PMID: 38173833)
Cancer Cell. 2022 Nov 14;40(11):1255-1263. (PMID: 36240779)
EClinicalMedicine. 2023 Jul 27;62:102113. (PMID: 37554126)
Cancer Discov. 2015 Jan;5(1):52-63. (PMID: 25361845)
Eur J Cancer. 2024 Mar;199:113564. (PMID: 38266541)
MAbs. 2021 Jan-Dec;13(1):1951427. (PMID: 34291723)
JCO Oncol Pract. 2023 Aug;19(8):539-546. (PMID: 37207306)
Genes (Basel). 2024 Jul 11;15(7):. (PMID: 39062682)
Ecancermedicalscience. 2021 Dec 13;15:ed119. (PMID: 35211208)
Cancers (Basel). 2023 Mar 13;15(6):. (PMID: 36980630)
Signal Transduct Target Ther. 2022 Mar 22;7(1):93. (PMID: 35318309)
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108. (PMID: 27026201)
Acta Pharm Sin B. 2023 Oct;13(10):4025-4059. (PMID: 37799390)
Int J Mol Sci. 2022 Mar 29;23(7):. (PMID: 35409110)
Int J Mol Sci. 2024 Jan 15;25(2):. (PMID: 38256137)
Lancet Oncol. 2019 May;20(5):663-673. (PMID: 30922733)
Mol Cancer Ther. 2018 Jan;17(1):243-253. (PMID: 29054985)
Ann Oncol. 2023 Feb;34(2):127-140. (PMID: 36372281)
Toxicol Pathol. 2018 Oct;46(7):746-752. (PMID: 30295169)
Cancers (Basel). 2023 Jan 24;15(3):. (PMID: 36765668)
J Gastrointest Oncol. 2016 Oct;7(5):797-803. (PMID: 27747093)
Cancers (Basel). 2023 May 05;15(9):. (PMID: 37174094)
Cancer Res. 1991 May 1;51(9):2286-90. (PMID: 2015593)
NPJ Precis Oncol. 2022 Dec 9;6(1):91. (PMID: 36494601)
Cancers (Basel). 2023 Sep 06;15(18):. (PMID: 37760415)
Pharmaceutics. 2023 Aug 19;15(8):. (PMID: 37631374)
Mol Cancer Ther. 2021 Jun;20(6):1112-1120. (PMID: 33722856)
Mol Cancer Res. 2020 Jan;18(1):3-19. (PMID: 31659006)
Crit Rev Oncol Hematol. 2024 Jun;198:104355. (PMID: 38621469)
Oncotarget. 2017 Jul 18;8(29):47052-47063. (PMID: 28423362)
Br J Cancer. 2020 Mar;122(5):603-612. (PMID: 31839676)
ESMO Open. 2022 Aug;7(4):100554. (PMID: 35963179)
Oncol Lett. 2017 Oct;14(4):3883-3892. (PMID: 28943897)
Cells. 2022 Feb 25;11(5):. (PMID: 35269424)
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):471-474. (PMID: 33641586)
ESMO Open. 2022 Feb;7(1):100378. (PMID: 35032765)
Protein Cell. 2018 Jan;9(1):33-46. (PMID: 27743348)
Mol Oncol. 2012 Apr;6(2):140-6. (PMID: 22356776)
Crit Rev Oncol Hematol. 2023 Apr;184:103960. (PMID: 36907365)
Gastro Hep Adv. 2022 Apr 15;1(4):618-626. (PMID: 39132071)
Front Oncol. 2022 Sep 23;12:961637. (PMID: 36212414)
NPJ Precis Oncol. 2018 Oct 3;2:21. (PMID: 30302397)
Cell Death Dis. 2017 Dec 13;8(12):3205. (PMID: 29235470)
Cancers (Basel). 2023 Mar 31;15(7):. (PMID: 37046766)
J Oncol Pract. 2018 Jul;14(7):437-441. (PMID: 29920138)
JAMA Oncol. 2022 Jul 1;8(7):1042-1046. (PMID: 35511148)
Cancer Commun (Lond). 2023 Mar;43(3):297-337. (PMID: 36357174)
Sensors (Basel). 2023 Dec 20;24(1):. (PMID: 38202898)
Mol Cancer Ther. 2016 Dec;15(12):2825-2834. (PMID: 27780876)
Sci Rep. 2022 Jun 17;12(1):10206. (PMID: 35715440)
Antibodies (Basel). 2023 Nov 03;12(4):. (PMID: 37987250)
Eur J Cancer. 2013 Jan;49(2):329-35. (PMID: 22947649)
Cancers (Basel). 2020 Jul 24;12(8):. (PMID: 32722188)
Arch Pathol Lab Med. 2011 Jan;135(1):55-62. (PMID: 21204711)
J Clin Oncol. 2008 Jan 1;26(1):20-5. (PMID: 18165636)
Oncol Rep. 2016 Jul;36(1):419-27. (PMID: 27177355)
Adv Sci (Weinh). 2020 Nov 03;7(24):2002852. (PMID: 33344137)
J Gastrointest Oncol. 2019 Aug;10(4):751-765. (PMID: 31392056)
Nat Rev Cancer. 2008 Jun;8(6):473-80. (PMID: 18469827)
Bioconjug Chem. 2023 Nov 15;34(11):1951-2000. (PMID: 37821099)
J Clin Oncol. 2021 Aug 1;39(22):2474-2485. (PMID: 33929895)
N Engl J Med. 2022 Jul 7;387(1):9-20. (PMID: 35665782)
Oncologist. 2018 Sep;23(9):1103-1108. (PMID: 29650683)
Cancer Discov. 2017 Jun;7(6):586-595. (PMID: 28365644)
J Clin Oncol. 2023 Nov 1;41(31):4852-4863. (PMID: 37694347)
J Clin Oncol. 2024 Jan 1;42(1):47-58. (PMID: 37870536)
Biomedicines. 2024 Feb 10;12(2):. (PMID: 38398017)
J Hematol Oncol. 2023 Jan 17;16(1):3. (PMID: 36650546)
N Engl J Med. 2024 Mar 7;390(10):875-888. (PMID: 38446675)
J Control Release. 2013 Dec 10;172(2):395-404. (PMID: 23880472)
Lancet Oncol. 2021 May;22(5):690-701. (PMID: 33798493)
Exp Biol Med (Maywood). 2018 Feb;243(3):213-221. (PMID: 29405771)
J Clin Oncol. 1998 Feb;16(2):397-404. (PMID: 9469321)
AAPS J. 2021 Apr 15;23(3):56. (PMID: 33856579)
Chem Rec. 2023 Dec;23(12):e202300293. (PMID: 38010365)
Eur J Cancer. 2023 Dec;195:113379. (PMID: 37913680)
N Engl J Med. 2010 Apr 8;362(14):1273-81. (PMID: 20375404)
Clin Cancer Res. 2017 Aug 1;23(15):4323-4334. (PMID: 28381415)
Cancer Cell Int. 2022 Aug 13;22(1):255. (PMID: 35964048)
EClinicalMedicine. 2020 Jul 31;25:100487. (PMID: 32775973)
BMC Cancer. 2013 Dec 30;13:615. (PMID: 24377754)
Lancet Oncol. 2021 Nov;22(11):1560-1572. (PMID: 34656226)

Keywords: anti-HER2; antibody–drug conjugate; biliary tract cancer; payload; targeted therapy

Date Created: 20241016 Latest Revision: 20241019

20241019

PMC11476249

10.3390/cancers16193345

39409965